Related Experiment Video
Updated: Jul 4, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Exploring the pharmacotherapeutic options for treating type 2 diabetes
1Division of Endocrinology, Diabetes, Bone and Mineral Disorders, Henry Ford Medical Center, Detroit, MI 48202, USA. Dkruger1@HFHS.org
The Diabetes Educator
|July 24, 2008
Summary
Type 2 diabetes is increasingly common, leading to severe health risks. Exenatide, a GLP-1 receptor agonist, offers an effective new treatment option when other methods fail.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes (T2D) prevalence is rising, with millions diagnosed and undiagnosed in the US.
- Poorly managed T2D increases risks of microvascular and macrovascular complications.
- Pathogenesis involves insulin resistance, impaired insulin secretion, and increased glucagon, leading to hyperglycemia, weight gain, hypertension, and dyslipidemia.
Purpose of the Study:
- To review the challenges in managing T2D.
- To introduce incretin mimetics, specifically glucagon-like peptide-1 (GLP-1) receptor agonists like exenatide, as a therapeutic option.
Main Methods:
- Review of current understanding of T2D pathogenesis and progression.
- Discussion of treatment algorithms, including lifestyle modifications, oral hypoglycemic agents, and insulin therapy.
- Evaluation of exenatide as a novel therapeutic agent.
Main Results:
- Despite lifestyle changes and oral agents, glycemic control can worsen.
- Exenatide, a GLP-1 receptor agonist, mimics natural GLP-1 action.
- Exenatide demonstrates efficacy as an adjunct therapy to oral hypoglycemic agents.
Conclusions:
- T2D management requires addressing impaired insulin secretion and resistance.
- Incretin mimetics like exenatide represent a significant advancement in T2D treatment.
- Exenatide provides an effective option for patients whose glycemic control is suboptimal despite existing therapies.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...